Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Ready To Launch OTC Nasonex In 2022

As Company Completes Divestiture Of Latin American Business

Executive Summary

Perrigo has received FDA approval for the OTC use of Nasonex 24-hour allergy (mometasone furoate monohydrate) 50mcg and plans to launch it later this year. The news comes after the company reported a healthy fourth quarter on the back of a strong rebound in the demand for cough/cold products, fresh from divesting its generic Rx prescription pharmaceutical business in 2021

You may also be interested in...



Perrigo Trades Rx For HRA With €1.8bn Acquisition

Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.

Perrigo Divests In Brazil And Mexico

Perrigo has revealed plans to divest its OTC businesses in Brazil and Mexico to private equity firm Advent International, citing insufficient scale and weak margins.

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel